Jonathan Todd Garland's Insider Trades & SAST Disclosures
Jonathan Todd Garland's most recent trade in Cytek BioSciences Inc was a trade of 2,761 Common Stock done . Disclosure was reported to the exchange on Aug. 18, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jonathan Todd Garland.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytek BioSciences Inc | Jonathan Todd Garland | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2023 | 2,761 | 9,839 | - | - | Common Stock | |
| Cytek BioSciences Inc | Jonathan Todd Garland | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2023 | 2,761 | 39,579 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Jonathan Todd Garland | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2023 | 1,951 | 7,838 | - | - | Common Stock | |
| Cytek BioSciences Inc | Jonathan Todd Garland | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2023 | 1,951 | 21,462 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Jonathan Todd Garland | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.46 per share. | 18 Aug 2023 | 1,076 | 8,763 | - | 8.5 | 9,103 | Common Stock |
| Cytek BioSciences Inc | Jonathan Todd Garland | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.46 per share. | 18 Aug 2023 | 760 | 7,078 | - | 8.5 | 6,430 | Common Stock |
| Cytek BioSciences Inc | Jonathan Todd Garland | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 7,804 | 7,804 | - | - | Common Stock | |
| Cytek BioSciences Inc | Jonathan Todd Garland | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 7,804 | 23,413 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Jonathan Todd Garland | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.69 per share. | 18 May 2023 | 3,040 | 4,764 | - | 6.7 | 20,338 | Common Stock |
| Cytek BioSciences Inc | Jonathan Todd Garland | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 1,840 | 6,604 | - | - | Common Stock | |
| Cytek BioSciences Inc | Jonathan Todd Garland | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 1,840 | 42,340 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Jonathan Todd Garland | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.69 per share. | 18 May 2023 | 717 | 5,887 | - | 6.7 | 4,797 | Common Stock |
| Cytek BioSciences Inc | Jonathan Todd Garland | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 66,773 | 66,773 | - | - | Employee Stock Option (right to buy) | |
| Cytek BioSciences Inc | Jonathan Todd Garland | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 44,180 | 44,180 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Jonathan Todd Garland | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2022 | 46,971 | 46,971 | - | - | Stock Option (right to buy) | |
| Cytek BioSciences Inc | Jonathan Todd Garland | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2022 | 31,217 | 31,217 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges